Skip to main content
SpringerLink
Log in

Immunological Adverse Effects of Interferon Treatment

  • Review Article
  • Adverse Effects and Interactions
  • Published:
Clinical Immunotherapeutics Aims and scope Submit manuscript

Summary

The immunological adverse effects of interferon treatment have become a matter of concern because of the widespread use of these agents. Interferons have various and profound effects on the immune system, such as modulation of immunoglobulin synthesis, T cell-mediated cytotoxicity and natural killer cell activity, and enhancement of the expression of major histocompatibility complex molecules. The major immunological adverse effects of interferons are aggravation of pre-existing autoimmune disorders, unmasking of silent autoimmune processes and induction of de novo autoimmunity. The possible development of almost all the organ-specific and nonspecific autoimmune diseases involving autoantibodies should be taken into account in interferon treatment. Thyroid autoimmune disorders are most frequently observed. Autoimmune complications induced by interferon are usually reversible by cessation of interferon treatment alone or by the additional administration of immunosuppressive treatment. However, some possible complications of interferon therapy, especially systemic lupus erythematosus and interstitial pneumonitis, should be recognised as life-threatening, and even fatal.

Allograft rejection in patients with liver or kidney transplants, and graft-versus-host disease in patients treated with bone marrow transplants, may develop following interferon treatment. Furthermore, contrary to the inhibitory effects of interferons on tumour growth, development of lymphoproliferative and myeloproliferative disorders, including plasma cell and myeloid leukaemia, and enhancement of metastases of malignant melanoma have also been observed. Finally, the emergence of anti-interferon antibodies may lead to loss of therapeutic activity and the requirement to employ another interferon preparation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Isaacs A, Lindenmann J. Virus interference. I. The interferon. Proc R Soc Lond B 1957; 147: 258–67

    Article  PubMed  CAS  Google Scholar 

  2. Harfäst B, Huddlestone JR, Casali P, et al. Interferon acts directly on human B lymphocytes to modulate immunoglobulin synthesis. J Immunol 1981; 127: 2146–50

    PubMed  Google Scholar 

  3. Lindahl P, Leary R, Gresser I. Enhancement by interferon of the specific cytotoxicity of sensitized lymphocytes. Proc Natl Acad Sci USA 1972; 69: 721–5

    Article  PubMed  CAS  Google Scholar 

  4. Scultz RM, Papamatheakis JD, Chirigos MA. Interferon: an inducer of macrophage activation by polyanions. Science 1977; 197: 674

    Article  Google Scholar 

  5. Gidlund M, Örn A, Wigzell H, et al. Enhanced NK cell activity in mice injected with interferon and interferon inducers. Nature 1978; 273: 759–61

    Article  PubMed  CAS  Google Scholar 

  6. Grander D, Öberg K, Lundqvist ML, et al. Interferon-induced enhancement of 2′,5′-oligoadenylate synthetase in mid-gut carcinoid tumours. Lancet 1990; 336: 337–40

    Article  PubMed  CAS  Google Scholar 

  7. Strander H. Interferon treatment of human neoplasia. In: Klein G, Weinhous S, editors. Advances in cancer research. V. London: Academic Press, 1986: 46–56

    Google Scholar 

  8. Cirelli R, Tyring SK. Major therapeutic uses of interferons. Clin Immunother 1995; 3(1): 27–87

    Article  Google Scholar 

  9. Müller U, Steinhoff U, Reis LFL, et al. Functional role of type I and type II interferons in antiviral defense. Science 1994; 264: 1918–21

    Article  PubMed  Google Scholar 

  10. Baglioni C, Maroney TA, West DK. 2′5′-oligo(A) polymerase activity and inhibition of viral RNA synthesis in interferon treated Hela cells. Biochemistry 1979; 18: 1765–70

    Article  PubMed  CAS  Google Scholar 

  11. Samuel CE. The interferon-induced protein P1/eIF-2 alpha kinase. In: Baron S, Stanton GJ, Fleischmann WR, editors. The interferon system: a current review to 1987. Austin: University of Texas Press, 1987: 373–81

    Google Scholar 

  12. Lindemann J, Haller O. MX protein pathway of interferon action. In: Baron S, Stanton GJ, Fleischmann WR, editors. The interferon system: a current review to 1987. Austin: University of Texas Press, 1987: 393–7

    Google Scholar 

  13. Monaco JJ. A molecular model of MHC class-I-restricted antigen processing. Immunol Today 1992; 13: 173–9

    Article  PubMed  CAS  Google Scholar 

  14. Cho S, Attaya M, Brown MG, et al. A cluster of transcribed sequences between the Pb and Ob genes of the murine major histocompatibility complex. Proc Natl Acad Sci USA 1991; 88: 5197–201

    Article  PubMed  CAS  Google Scholar 

  15. Porber JS, Collins T, Michael A, et al. Lymphocytes recognize human vascular endothelial and dermal fibroblast la antigens induced by recombinant immune interferon. Nature 1983; 305: 726–9

    Article  Google Scholar 

  16. Fentiman IS, Thomas BS, Balkwill FR, et al. Primary hypothyroidism associated with interferon therapy of breast cancer. Lancet 1985; 1: 1166

    Article  PubMed  CAS  Google Scholar 

  17. Burman P, Totterman TH, Oberg K, et al. Thyroid autoimmunity in patients on long term therapy with leukocyte-derived interferon. J Clin Endocrinol Metab 1986; 63: 1086–90

    Article  PubMed  CAS  Google Scholar 

  18. Gisslinger H, Gilly B, Woloszczuk W, et al. Thyroid autoimmunity and hypothyroidism during long-term treatment with recombinant interferon-alpha. Clin Exp Immunol 1992; 90: 363–7

    Article  PubMed  CAS  Google Scholar 

  19. Berris B, Feinman SV. Thyroid dysfunction and liver injury following alpha-interferon treatment of chronic viral hepatitis. Dis Dig Sci 1991; 36: 1657–60

    Article  CAS  Google Scholar 

  20. Lisker-Melman M, Di Bisceglie AM, Usala SJ, et al. Development of thyroid disease during therapy of chronic viral hepatitis with interferon alpha. Gastroenterology 1992; 102: 2155–60

    PubMed  CAS  Google Scholar 

  21. Schultz M, Muller R, von zur Muhlen A, et al. Induction of hyperthyroidism by interferon alpha-2b. Lancet 1989; 1: 1452

    Article  PubMed  CAS  Google Scholar 

  22. Rönnblom LE, Alm GV, Öberg K. Autoimmune phenomena in patients with malignant carcinoid tumors during interferon-alpha treatment. Acta Oncol 1991; 30: 537–40

    Article  PubMed  Google Scholar 

  23. Mayet WJ, Hess G, Gerken G, et al. Treatment of chronic type B hepatitis with recombinant alfa interferon induces autoantibodies not specific for autoimmune chronic hepatitis. Hepatology 1989; 10: 24–8

    Article  PubMed  CAS  Google Scholar 

  24. Saracco G, Touscoz A, Durazzo M, et al. Autoantibodies and response to alpha-interferon in patients with chronic viral hepatitis. J Hepatol 1990; 11: 339–43

    Article  PubMed  CAS  Google Scholar 

  25. Picciotto A, Varagona G, Cianciosi P, et al. Thyroid function and interferon treatment in chronic hepatitis C. Gut 1993; 34: 574

    Article  PubMed  CAS  Google Scholar 

  26. Marcellin P, Pouteau M, Renard P, et al. Sustained hypothyroidism induced by recombinant alpha interferon in patients with chronic hepatitis C. Gut 1992; 33: 855–6

    Article  PubMed  CAS  Google Scholar 

  27. Taniguchi Y, Marukami T, Nakanishi K, et al. Two cases of hypothyroidism associated with alpha-interferon therapy. Intern Med 1992; 31: 373–6

    Article  PubMed  CAS  Google Scholar 

  28. Conlon KC, Urba WJ, Smith JW, et al. Exacerbation of symptoms of autoimmune disease in patients receiving alpha-interferon therapy. Cancer 1990; 65: 2237–42

    Article  PubMed  CAS  Google Scholar 

  29. Giles FJ, Worman CP, Jewell AP, et al. Recombinant alpha-interferons, thyroid irradiation and thyroid disease. Acta Haematol 1991; 85: 160–3

    Article  PubMed  CAS  Google Scholar 

  30. Kamikubo K, Takami R, Suwa T, et al. Silent thyroiditis developed during alpha-interferon therapy. Am J Med Sci 1993; 306: 174–6

    Article  PubMed  CAS  Google Scholar 

  31. Koizumi S, Mashio Y, Mizuo H, et al. Graves’ hyperthyroidism following transient thyrotoxicosis during interferon therapy for chronic hepatitis C. Intern Med 1995; 34: 58–60

    Article  PubMed  CAS  Google Scholar 

  32. Sauter NP, Atkins MB, Mier JW, et al. Transient thyrotoxicosis and persistent hypothyroidism due to acute autoimmune thyroiditis after interleukin-2 and interferon-alpha therapy for metastatic carcinoma. Am J Med 1992; 92: 441–4

    Article  PubMed  CAS  Google Scholar 

  33. Pagliacci MC, Pelicci G, Schippa M, et al. Does interferon-beta therapy induce thyroid autoimmune phenomena? Horm Metab Res 1991; 23: 196–7

    Article  PubMed  CAS  Google Scholar 

  34. Bhakri H, Sriskandan K, Davis T, et al. Recombinant gamma interferon and autoimmune thyroid disease. Lancet 1985; ii: 457

    Article  Google Scholar 

  35. Kung AW, Jones BM, Lai CL. Effects of interferon-gamma therapy on thyroid function, T-lymphocyte subpopulations and induction of autoantibodies. J Clin Endocrinol Metab 1990; 71: 1230–4

    Article  PubMed  CAS  Google Scholar 

  36. Ueda S, Yoshikawa M, Okamoto S, et al. Thyroid dysfunction following alpha-interferon treatment for chronic hepatitis C. J Nara Med Assoc 1994; 45: 192–9

    Google Scholar 

  37. Fonseca V, Thomas M, Dusheiko G. Thyrotropin receptor antibodies following treatment with recombinant alpha-interferon in patients with hepatitis. Acta Endocrinol 1991; 125: 491–3

    PubMed  CAS  Google Scholar 

  38. Papo T, Oksenhendler E, Izembart M, et al. Antithyroid hormone antibodies induced by interferon-alpha. J Clin Endocrinol Metab 1992; 75: 1484–6

    Article  PubMed  CAS  Google Scholar 

  39. Pichert G, Jost LM, Zobeli L, et al. Thyroiditis after treatment with interleukin-2 and interferon alpha-2a. Br J Cancer 1990; 62: 100–3

    Article  PubMed  CAS  Google Scholar 

  40. Jacob EL, Clare-Salzler MJ, Chopra IJ, et al. Thyroid function abnormalities associated with the chronic outpatient administration of recombinant interleukin-2 and recombinant interferon-alpha. J Immunother 1991; 10: 448–55

    Article  Google Scholar 

  41. Scalzo S, Gengaro A, Boccoli G, et al. Primary hypothyroidism associated with interleukin-2 and interferon alpha-2 therapy of melanoma and renal cell carcinoma. Eur J Cancer 1990; 26: 1152–6

    Article  PubMed  CAS  Google Scholar 

  42. Bottazzo GF, Pujol-Borrell R, Hanafusa T, et al. Role of aberrant HLA-DR expression and antigen presentation in induction of endocrine autoimmunity. Lancet 1983; ii: 1115–9

    Article  Google Scholar 

  43. Hanafusa T, Pujol-Borrell R, Chiovato L, et al. Aberrant expression of HLA-DR antigen on thyrocytes in Graves’ disease: relevance for autoimmunity. Lancet 1983; ii: 1111–5

    Article  Google Scholar 

  44. Todd I, Pujol-Borrell R, Hammond LJ, et al. Interferon-gamma induces HLA-DR expression by thyroid epithelium. Clin Exp Immunol 1985; 61: 265–73

    PubMed  CAS  Google Scholar 

  45. Katayama K, Hayashi N, Takehara T, et al. Alpha-interferon enhances gamma-interferon production of peripheral blood mononuclear cells pre-activated with phytohemoagglutinin. Gastroenterol Jpn 1993; 28: 673–8

    PubMed  CAS  Google Scholar 

  46. Romagnani S, Del Prete GF, Maggi E, et al. TH1 and TH2 cells and their role in diseases. ACI News 1993; 5: 19–22

    Google Scholar 

  47. Daniels HM, Meager A, Eddieston ALWF, et al. Spontaneous production of tumor necrosis factor alpha and interleukin-1 beta during interferon-alpha treatment of chronic HBV infection. Lancet 1990; 335: 875–7

    Article  PubMed  CAS  Google Scholar 

  48. Buscema M, Todd I, Deuss, et al. Influence of tumor necrosis factor-alpha on the modulation by interferon-gamma of HLA class II molecules in human thyroid cells and its effect on interferon-gamma binding. J Clin Endocrinol Metab 1989; 69: 433–9

    Article  PubMed  CAS  Google Scholar 

  49. Jacob CO. Tumor necrosis factor alpha in autoimmunity: pretty girl or old witch? Immunol Today 1992; 13: 122–5

    Article  PubMed  CAS  Google Scholar 

  50. Leeuwenberg JFM, Van Damme J, Jeunhomme TMAA, et al. Effects of tumor necrosis factor on the interferon-gamma-induced major histocompatibility complex class II antigen expression by human endothelial cells. Eur J Immunol 1988; 18: 1469–72

    Article  PubMed  CAS  Google Scholar 

  51. Gemlo BT, Palladino MA, Jaffe HS, et al. Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokine-activated killer cells. Cancer Res 1988; 48: 5864–7

    PubMed  CAS  Google Scholar 

  52. Reem GF, Yeh NH. Interleukin-2 regulates expression of its receptor and synthesis of gamma interferon by human T lymphocytes. Science 1984; 225: 429–30

    Article  PubMed  CAS  Google Scholar 

  53. Nedwin GE, Svedersky LP, Bringman TS, et al. Effect of interleukin-2, interferon gamma and mitogens on the production of tumor necrosis factors alpha and beta. J Immunol 1985; 135: 2492–7

    PubMed  CAS  Google Scholar 

  54. Der Prete GF, Tiri A, Mariotti S, et al. Enhanced production of gamma-interferon by thyroid-derived T cell clones from patients with Hashimoto’s thyroiditis. Clin Exp Immunol 1987; 69: 323–31

    PubMed  Google Scholar 

  55. Migita K, Eguchi K, Tezuka H, et al. Cytotoxic activity of interleukin-2 activated killer cells toward thyroid epithelial cells. Clin Exp Immunol 1989; 77: 196–201

    PubMed  CAS  Google Scholar 

  56. Nagayama Y, Izumi M, Ashizawa K, et al. Inhibitory effect of interferon-gamma on the response of human thyrocytes to thyrotropin (TSH) stimulation: relationship between the response to TSH and the expression of DR antigen. J Clin Endocrinol Metab 1987; 64: 949–53

    Article  PubMed  CAS  Google Scholar 

  57. Yamazaki K, Kanaji Y, Shizume K, et al. Reversible inhibition by interferons alpha and beta of 125I incorporation and thyroid hormone release by human thyroid follicles in vitro. J Clin Endocrinol Metab 1993; 77; 1439–41

    Article  PubMed  CAS  Google Scholar 

  58. Sato K, Satoh T, Shizume K, et al. Inhibition of 125I organification and thyroid hormone release by interleukin-1, tumor necrosis factor-alpha, and interferon-gamma in human thyrocytes in suspension culture. J Clin Endocrinol Metab 1990; 70: 1735–43

    Article  PubMed  CAS  Google Scholar 

  59. Heremans H, Billiau A, Colombatti A, et al. Interferon treatment of NZB mice: accelerated progression of autoimmune disease. Infect Immun 1978; 21; 925–30

    PubMed  CAS  Google Scholar 

  60. Gresser I, Maury C, Tovey M, et al. Progressive glomerulonephritis in mice treated with interferon preparations at birth. Nature 1974; 263: 420–2

    Article  Google Scholar 

  61. Hooks JJ, Moutsopoulos HM, Geis SA, et al. Immune interferon in the circulation of patients with autoimmune disease. N Engl J Med 1979; 301: 5–8

    Article  PubMed  CAS  Google Scholar 

  62. Kim T, Kanayama Y, Negoro M, et al. Serum levels of interferons in patients with systemic lupus erythematosus. Clin Exp Immunol 1987; 70: 562–9

    PubMed  CAS  Google Scholar 

  63. Machold KP, Smolen JS. Interferon-gamma induced exacerbation of systemic lupus erythematosus. J Rheumatol 1990; 17: 831–2

    PubMed  CAS  Google Scholar 

  64. Schilling PJ, Kurzrock R, Kantariian H, et al. Development of systemic lupus erythematosus after interferon therapy for chronic myelogenous leukemia. Cancer 1991; 68: 1536–7

    Article  PubMed  CAS  Google Scholar 

  65. Rönnblom LE, Alm GV, Öberg KE. Possible induction of systemic lupus erythematosus by interferon-alpha treatment in a patient with a malignant carcinoid tumour. J Intern Med 1990; 227: 207–10

    Article  PubMed  Google Scholar 

  66. Graninger WB, Hassfeld W, Pesau BB, et al. Induction of systemic lupus erythematosus by interferon-gamma in a patient with rheumatoid arthritis. J Rheumatol 1991; 18: 1621–2

    PubMed  CAS  Google Scholar 

  67. Tolaymat A, Leventhal B, Sakarcan A, et al. Systemic lupus erythematosus in a child receiving long-term interferon. J Pediatr 1992; 120: 429–32

    Article  PubMed  CAS  Google Scholar 

  68. Öberg KE. Development of an SLE syndrome in a patient with malignant carcinoid tumor after treatment with alpha interferon. Interferons Cytokines 1989; 12: 30–2

    Google Scholar 

  69. Mehta ND, Hooberman AL, Vokes EE, et al. 35-year-old patient with chronic myelogenous leukemia developing systemic lupus erythematosus after alpha-interferon therapy. Am J Hematol 1992; 41: 141

    Article  PubMed  CAS  Google Scholar 

  70. Wandl UB, Nagel-Hiemke M, May D, et al. Lupus-like autoimmune disease induced by interferon therapy for myeloproliferative disorders. Clin Immunol Immunopathol 1992; 65: 70–4

    Article  PubMed  CAS  Google Scholar 

  71. Chazerain P, Meyer O, Kahn MF. Rheumatoid arthritis-like disease after alpha-interferon therapy. Ann Intern Med 1992; 116: 427

    PubMed  CAS  Google Scholar 

  72. Ueno Y, Sohma T. Alpha-interferon-induced nodular rheumatoid arthritis in renal cell carcinoma. Ann Intern Med 1992; 117: 266–7

    PubMed  CAS  Google Scholar 

  73. O’Connell PG, Gerber LH, Digiovanna JJ, et al. Arthritis in patients with psoriasis treated with gamma-interferon. J Rheumatol 1992; 19: 80–2

    PubMed  Google Scholar 

  74. Taylor HG, Davis MJ, Hothersall TE. Hairy cell leukemia and rheumatoid arthritis. Br J Rheumatol 1991; 30: 391–2

    Article  PubMed  CAS  Google Scholar 

  75. Maccari S, Bassi C, Giovannini AG, et al. A case of arthropathy and hypothyroidism during recombinant alpha-interferon therapy. Clin Rheumatol 1991; 10: 452–4

    Article  PubMed  CAS  Google Scholar 

  76. Chan GCB, Lee SS, Yeoh EK. Mono-arthritis in a chronic hepatitis B patient after alpha-interferon treatment. J Gastroenterol Hepatol 1992; 7: 432–3

    Article  PubMed  CAS  Google Scholar 

  77. Kiely PDW, Bruckner FE. Acute arthritis following interferon-alpha therapy. Br J Rheumatol 1994; 33: 502–3

    Article  PubMed  CAS  Google Scholar 

  78. Jucgla A, Marcoval J, Curco N, et al. Psoriasis with articular involvement induced by interferon alpha. Arch Dermatol 1991; 127: 910–1

    Article  PubMed  CAS  Google Scholar 

  79. Cannon GW, Pincus SH, Emkey RD, et al. Double-blind trial of recombinant gamma-interferon versus placebo in the treatment of rheumatoid arthritis. Arthritis Rheum 1989; 32: 964–73

    Article  PubMed  CAS  Google Scholar 

  80. Veys EM, Mielants H, Verbruggen G, et al. Interferon gamma in rheumatoid arthritis — a double blind study comparing human recombinant interferon gamma with placebo. J Rheumatol 1988; 15: 570–4

    PubMed  CAS  Google Scholar 

  81. Mauritz NJ, Holmdahl R, Jonsson R, et al. Treatment with gamma interferon triggers the onset of collagen arthritis in mice. Arthritis Rheum 1988; 31: 1297–304

    Article  PubMed  CAS  Google Scholar 

  82. Rosenbach TO, Zor U, Baratz M, et al. Induction of acute synovitis in the rat by human interferon. Clin Exp Rheumatol 1987; 5: 35–40

    PubMed  CAS  Google Scholar 

  83. Jacob CO, Holoshitz J, van der Meide P, et al. Heterogenous effects of IFN-gamma in adjuvant arthritis. J Immunol 1989; 142: 1500–5

    PubMed  CAS  Google Scholar 

  84. Amento EP, Bhan AK, McCullagh KG, et al. Influences of gamma interferon on synovial fibroblast-like cells: la induction and inhibition of collagen synthesis. J Clin Invest 1985; 76: 837–48

    Article  PubMed  CAS  Google Scholar 

  85. Harrison PV, Peat MJ. Effect of interferon on psoriasis. Lancet 1986; ii: 457–8

    Article  Google Scholar 

  86. Georgetson MJ, Yarze JC, Lalos AT, et al. Exacerbation of psoriasis due to interferon-alpha treatment of chronic active hepatitis. Am J Gastroenterol 1993; 88; 1756–8

    PubMed  CAS  Google Scholar 

  87. Funk J, Langerland T, Schrumpf E, et al. Psoriasis induced by interferon-alpha. Br J Dermatol 1991; 125: 463–5

    Article  PubMed  CAS  Google Scholar 

  88. Quesada JR, Gutterman JU. Psoriasis and alpha interferon. Lancet 1986; i: 1466–8

    Article  Google Scholar 

  89. Kusec R, Ostojic S, Planinc-Peraica A, et al. Exacerbation of psoriasis after treatment with alpha interferon [letter]. Dermatologica 1990; 181: 170

    Article  PubMed  CAS  Google Scholar 

  90. Pauluzzi P, Kokelj F, Perkan V, et al. Psoriasis exacerbation induced by interferon-alpha. Report of two cases [letter]. Acta Derm Venereol 1993; 73: 395

    PubMed  CAS  Google Scholar 

  91. Kowalzick L, Weyer U. Psoriasis induced at the injection site of recombinant interferons. Arch Dermatol 1990; 126: 1515–6

    Article  PubMed  CAS  Google Scholar 

  92. Fierlbeck G, Rassner G, Muller C. Psoriasis induced at the injection site of recombinant interferon gamma. Arch Dermatol 1990; 126: 351–5

    Article  PubMed  CAS  Google Scholar 

  93. Gottlieb AB. Immunologic mechanisms in psoriasis. J Am Acad Dermatol 1988; 18: 1376–80

    Article  PubMed  CAS  Google Scholar 

  94. Gottlieb AB, Lifshitz B, Fu SM, et al. Expression of HLA-DR molecules by keratinocytes. and presence of Langerhans cells in the dermal infiltrate of active psoriatic plaques. J Exp Med 1986; 164: 1013–28

    Article  PubMed  CAS  Google Scholar 

  95. Baker BS, Griffiths CEM, Fry L, et al. Psoriasis and interferon [letter]. Lancet 1986; ii: 342

    Article  Google Scholar 

  96. Basham TY, Nickoloff BJ, Merigan TC, et al. Recombinant gamma interferon induces HLA-DR expression on cultured human keratinocytes. J Invest Dermatol 1984; 83: 88–90

    Article  PubMed  CAS  Google Scholar 

  97. Oeda E, Shinohara K. Cutaneous necrosis caused by injection of alpha-interferon in a patient with chronic myelogenous leukemia [letter]. Am J Hematol 1993; 44: 213–4

    Article  PubMed  CAS  Google Scholar 

  98. Cnudde F, Charakhanian S, Luboinski J, et al. Cutaneous local necrosis following interferon injection. Int J Dermatol 1991; 30: 147

    Article  PubMed  CAS  Google Scholar 

  99. Orlow SJ, Friedman-Kien AE. Cutaneous ulcerations secondary to interferon alpha therapy to Kaposi’s sarcoma. Arch Dermatol 1992; 128: 566

    Article  PubMed  CAS  Google Scholar 

  100. Reid TJ, Lombardo FA, Redmond J, et al. Digital vasculitis associated with interferon therapy. Am J Med 1992; 92: 702–3

    Article  PubMed  Google Scholar 

  101. Sangster G, Kaye SB, Caiman KC, et al. Cutaneous vasculitis associated with interferon. Eur J Cancer Clin Oncol 1883; 19: 1647

    Article  Google Scholar 

  102. Strumia R, Venturini D, Boccia S. UVA and interferon-alfa therapy in a patient with lichen planus and chronic hepatitis C. Int J Dermatol 1993; 22: 386

    Article  Google Scholar 

  103. Papini M, Bruni PL, Bettacchi A, et al. Sudden onset of oral ulcerative lichen in a patient with chronic hepatitis C on treatment with alpha-interferon. Int J Dermatol 1994; 33: 221–2

    PubMed  CAS  Google Scholar 

  104. Detmar U, Agathos M, Nerl C. Allergy of delayed type to recombinant interferon alpha-2C. Contact Dermatitis 1989; 20: 149–50

    Article  PubMed  CAS  Google Scholar 

  105. Pigatto PD, Bigardi A, Legori A. Allergic contact dermatitis from beta-interferon in eyedrops. Contact Dermatitis 1991; 25: 199–200

    Article  PubMed  CAS  Google Scholar 

  106. Parodi A, Semino M, Gallo R, et al. Bullous eruption with circulating pemphigus-like antibodies following interferon-alpha therapy. Dermatology 1993; 186: 155–7

    Article  PubMed  CAS  Google Scholar 

  107. Ramseur WL, Richards F, Duggan DB. A case of fatal pemphigus vulgaris in association with beta interferon and interleukin-2 therapy. Cancer 1989: 63; 2005–7

    Article  PubMed  CAS  Google Scholar 

  108. Hoofnagle JH, Peters M, Mullen KD, et al. Randomized controlled trial of recombinant human alpha-interferon in patients with chronic hepatitis B. Gastroenterol 1988; 95: 1318–25

    CAS  Google Scholar 

  109. Alexander GJM, Brahm J, Fagan EA, et al. Loss of HBsAg with interferon therapy in chronic hepatitis B virus infection. Lancet 1987; ii: 66–8

    Article  Google Scholar 

  110. Laskus T, Radkowski M, Slusarczyk J, et al. Severe exacerbation of chronic active hepatitis B during interferon alpha therapy. Digestion 1992; 52: 61–4

    Article  PubMed  CAS  Google Scholar 

  111. Kassianides C, Di Bisceglie AM, Hoofnagle JH, et al. Alpha-interferon therapy in patients with decompensated chronic type B hepatitis. In: Zuckerman AJ, editor. Viral hepatitis and liver disease. New York: Liss, 1988: 840–3

    Google Scholar 

  112. Janssen HLA, Brouwer JT, Nevens F, et al. Fetal hepatic decompensation associated with interferon-alpha. BMJ 1933; 306: 107–8

    Article  Google Scholar 

  113. Garcia-Buey L, Rodriguez-Gomez S, Garcia-Monzon R, et al. Triggering of latent autoimmune chronic active hepatitis (AICAH) by interferon therapy in chronic hepatitis C (CHC) [abstract]. J Hepatol 1993; 18 Suppl. 1: 126

    Google Scholar 

  114. Shindo M, Di Bisceglie AM, Hoofnagle JH. Acute exacerbation of liver disease during interferon alpha therapy for chronic hepatitis C. Gastroenterology 1992; 102: 1406–8

    PubMed  CAS  Google Scholar 

  115. Papo T, Marcellin P, Bernuau J, et al. Autoimmune chronic hepatitis exacerbated by alpha-interferon. Ann Intern Med 1992; 116: 51–3

    PubMed  CAS  Google Scholar 

  116. Ruiz-Mereno M, Rua MJ, Carreno V, et al. Autoimmune chronic hepatitis type 2 manifested during interferon therapy in children. Hepatology 1991; 12: 265–6

    Article  Google Scholar 

  117. Vento S, Di Perri G, Garofano T, et al. Hazards of interferon therapy for HBV-seronegative chronic hepatitis. Lancet 1989; ii: 926

    Article  Google Scholar 

  118. Silva MO, Reddy KR, Jeffers LJ, et al. Interferon-induced chronic active hepatitis? Gastroenterology 1991; 101: 840–2

    PubMed  CAS  Google Scholar 

  119. Ariad S, Song E, Cohen R, et al. Interferon-alpha induced autoimmune hepatitis in a patient with Philadelphia chromosome-positive chronic myeloid leukemia with cytogenetically normal T lymphocytes. Mol Biother 1992; 4: 139–42

    Article  PubMed  CAS  Google Scholar 

  120. Féray C, Samuel D, Gigou M, et al. Effects of interferon alpha in liver recipients with post-transplantation chronic hepatitis C [abstract]. J Hepatol 1994; 21 Suppl. 1: S11

    Google Scholar 

  121. Jain A, Jabbour N, Ramus H, et al. Incidence and severity of liver allograft rejection following institution of alpha-interferon for the treatment of viral hepatitis in liver transplant patients [abstract]. Gastroenterology 1993; 104: A922

    Google Scholar 

  122. Dousset B, Calmus Y, Conti F, et al. Irreversible rejection following treatment of recurrent hepatitis C after liver transplantation [abstract]. Hepatology 1993; 18: 329A

    Article  Google Scholar 

  123. Wright TL, Combs C, Kim M, et al. Interferon-α therapy for hepatitis C virus infection after liver transplantation. Hepatology 1994; 20: 773–9

    Article  PubMed  CAS  Google Scholar 

  124. McNair ANB, Jacyna MR, Thomas HC. Severe haemolytic transfusion reaction occurring during alpha-interferon therapy for chronic hepatitis. Eur J Gastroenterol Hepatol 1991; 3: 193–5

    Google Scholar 

  125. Akard LP, Hoffman R, Elias L, et al. Alpha-interferon and immune hemolytic anemia. Ann Intern Med 1986; 105: 306

    PubMed  CAS  Google Scholar 

  126. Braathen LR, Stavern P. Autoimmune haemolytic anaemia associated with interferon alpha-2a in patients with mycosis fungoides. BMJ 1989; 298: 1713

    Article  PubMed  CAS  Google Scholar 

  127. Quesada JR, Talpaz M, Rios A, et al. Clinical toxicity of interferon in cancer patients: a review. J Clin Oncol 1986; 4; 234–43

    PubMed  CAS  Google Scholar 

  128. Perez R, Padavic K, Krigel R, et al. Antierythrocyte autoantibody formation after therapy with interleukin-2 and gamma-interferon. Cancer 1991; 67: 2512–7

    Article  PubMed  CAS  Google Scholar 

  129. Rabinowitz AP, Hu E, Watkins K, et al. Hemolytic anemia in a cancer patient treated with recombinant interferon-gamma. J Biol Response Mod 1990; 9: 256–9

    PubMed  CAS  Google Scholar 

  130. Proctor SJ, Jackson G, Carey P, et al. Improvement of platelet counts in steroid-unresponsive idiopathic immune thrombocytopenic purpura after short-course therapy with recombinant alpha-2b interferon. Blood 1989; 74: 1894–7

    PubMed  CAS  Google Scholar 

  131. Benjamin S, Bain BJ, Dodsworth H. Severe bleeding associated with worsening thrombocytopenia following alpha interferon therapy for autoimmune thrombocytopenic purpura. Clin Lab Haematol 1990; 13: 315–7

    Article  Google Scholar 

  132. Matthey F, Ardeman S, Jones L, et al. Bleeding in immune thrombocytopenic purpura after alpha-interferon. Lancet 1990; 335: 471–2

    Article  PubMed  CAS  Google Scholar 

  133. McLaughlin P, Talpaz M, Quesada JR, et al. Immune thrombocytopenia following alpha-interferon therapy in patients with cancer. JAMA 1985; 253: 1353–4

    Article  Google Scholar 

  134. Kanfer EJ, McCarthy DM. Immune thrombocytopenia and interferon alfa. BMJ 1988; 297: 1613

    Article  PubMed  CAS  Google Scholar 

  135. Lopez-Morante AJ, Saez-Royuela F, Casanova Vareno F, et al. Immune thrombocytopenia after alpha-interferon therapy in a patient with chronic hepatitis C. Am J Gastroenterol 1992; 87: 809–10

    PubMed  CAS  Google Scholar 

  136. Abdi EA, Brien W, Venner PM. Auto-immune thrombocytopenia related to interferon therapy. Scand J Haematol 1986; 36: 515–9

    Article  PubMed  CAS  Google Scholar 

  137. Fornaciari G, Bassi C, Beltrami M, et al. Hemolytic anemia secondary to interferon treatment for chronic B hepatitis. J Clin Gastroenterol 1991: 13: 596–7

    PubMed  CAS  Google Scholar 

  138. Castenskiold EC, Colvin BT, Kelsey SM. Acquired factor VIII inhibitor associated with chronic interferon-alpha therapy in a patient with haemophilia A. Br J Haematol 1994; 87: 434–6

    Article  PubMed  CAS  Google Scholar 

  139. Stricker RB, Barlogie B, Kiprov DD. Acquired factor VIII inhibitor associated with chronic interferon-aha therapy. J Rheumatol 1994; 21: 350–2

    PubMed  CAS  Google Scholar 

  140. Aronson DL. Cause of death in hemophilia A in the United States from 1968 to 1979. Am J Hematol 1988; 27: 7–12

    Article  PubMed  CAS  Google Scholar 

  141. Bosi E, Bottazzo GF. Autoimmunity in insulin-dependent diabetes mellitus: implications for prediction and therapy. Clin Immunother 1995; 3(2): 125–35

    Article  Google Scholar 

  142. Foulis AK, Farquharson MA. Aberrant expression of HLA-DR antigens by insulin containing beta cells in recent onset type 1 (insulin-dependent) diabetes. Diabetes 1986; 35: 1215–24

    Article  PubMed  CAS  Google Scholar 

  143. Foulis AK, Farquharson MA, Hardman R. Aberrant expression of class II major histocompatibility complex molecules by β cells and hyperexpression of class I major histocompatibility complex molecules by insulin containing islets in type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1987; 30: 333–43

    Article  PubMed  CAS  Google Scholar 

  144. Miler BJ, Appel MC, O’Neil JJ, et al. Both the Lyt-2+ and L3T4+ T cell subsets are required for the transfer of diabetes in non-obese diabetic mice. J Immunol 1988; 140: 52–58

    Google Scholar 

  145. Haskins K, Portas M, Bergman B, et al. Pancreatic islet-specific T-cell clones from nonobese diabetic mice. Proc Natl Acad Sci USA 1989; 86: 8000–4

    Article  PubMed  CAS  Google Scholar 

  146. Bradley BJ, Haskins K, La Rosa FG, et al. CD8 T cells are not required for islet destruction induced by a CD4+ islet-specific T-cell clone. Diabetes 1992; 41: 1603–8

    Article  PubMed  CAS  Google Scholar 

  147. Stewart TA, Hultgren B, Huang X, et al. Induction of type I diabetes by interferon-alfa in transgenic mice. Science 1993; 260: 1942–6

    Article  PubMed  CAS  Google Scholar 

  148. Waguri M, Hanafusa T, Itoh N, et al. Occurrence of IDDM during interferon therapy for chronic viral hepatitis. Diabetes Res Clin Pract 1994; 23: 33–6

    Article  PubMed  CAS  Google Scholar 

  149. Fabris P, Betterle C, Floreani A, et al. Development of type 1 diabetes mellitus during interferon alpha therapy for chronic HCV hepatitis. Lancet 1992; 340: 548

    Article  PubMed  CAS  Google Scholar 

  150. Guerci AP, Guerci B, Levy-Marchal C, et al. Onset of insulin-dependent diabetes mellitus after interferon-alpha therapy for hairy cell leukemia. Lancet 1994; 343: 1167–8

    Article  PubMed  CAS  Google Scholar 

  151. Lopes EPA, Oliveira PM, Silva AE, et al. Exacerbation of type 2 diabetes mellitus during interferon-alpha therapy for chronic hepatitis B. Lancet 1994; 343: 244

    Article  PubMed  CAS  Google Scholar 

  152. Koivisto VA, Peklonen R, Cantel K. Effect of interferon on glucose tolerance and insulin sensitivity. Diabetes 1989; 38: 641–7

    Article  PubMed  CAS  Google Scholar 

  153. Krug J, Fritzsch J, Aust G. Induction of insulin antibodies and insulin allergy under alpha-interferon treatment of renal cell carcinoma in a patient with insulin-treated diabetes mellitus. Int Arch Allergy Immunol 1995; 106: 169–72

    Article  PubMed  CAS  Google Scholar 

  154. Sungur C, Ozyilkan E, Akpolat T, et al. Relapse of minimal change disease associated with alpha-interferon therapy. Nephron 1993; 65: 648

    Article  PubMed  CAS  Google Scholar 

  155. Nair S, Johnston J, Ernstoff MS, et al. Interferon-induced reversible acute renal failure with nephrotic syndrome. Urology 1992; 39: 169–72

    Article  PubMed  CAS  Google Scholar 

  156. Kurschel E, Metz-Kurschel U, Niederle N, et al. Investigations on the subclinical and clinical nephrotoxicity of interferon alpha-2B in patients with myeloproliferative syndromes. Ren Fail 1991; 13: 87–93

    Article  PubMed  CAS  Google Scholar 

  157. Selby P, Kohn J, Raymond J, et al. Nephrotic syndrome during treatment with interferon [letter]. BMJ 1985; 290: 1180

    Article  PubMed  CAS  Google Scholar 

  158. Averbuch SD, Austin HA, Sherwin SA, et al. Acute interstitial nephritis with the nephrotic syndrome following recombinant leukocyte-alpha interferon therapy for mycosis fungoides. N Engl J Med 1984; 310: 32–4

    Article  PubMed  CAS  Google Scholar 

  159. Lederer E, Truong L. Unusual glomerular lesion in a patient receiving long-term interferon alpha. Am J Kidney Dis 1992; 10: 516–8

    Google Scholar 

  160. Ault BH, Stapleton FB, Garber L, et al. Acute renal failure during therapy with recombinant human gamma interferon. N Engl J Med 1988; 319: 1397–400

    Article  PubMed  CAS  Google Scholar 

  161. Herrman J, Gabriel F. Membranoproliferative glomerulonephritis in a patient with hairy-cell leukemia treated with alpha-II interferon. Lancet 1987; 316: 112–3

    CAS  Google Scholar 

  162. Morel-Maroger L, Sloper JC, Vinter J, et al. An ultrastructural study of the development of nephritis in mice treated with interferon in the neonatal period. Lab Invest 1978; 39: 513–22

    PubMed  CAS  Google Scholar 

  163. Ayub A, Zafar M, Al-Harbi A, et al. Acute renal failure with alpha-interferon therapy: a case report. Med Sci Res 1993; 21: 123–4

    Google Scholar 

  164. Murata M, Nagai M, Bando S, et al. Emergence of acute interstitial pneumonia following high dose interferon alpha treatment in a case of chronic myelogenous leukemia. Intern Med 1993; 32: 716–8

    Article  PubMed  CAS  Google Scholar 

  165. Kamisako T, Adachi Y, Chihara I, et al. Interstitial pneumonitis and interferon-alpha. BMJ 1993; 306: 896

    Article  PubMed  CAS  Google Scholar 

  166. Yamaryo T, Nagai H, Kurashima A, et al. Two cases of interstitial pneumonia induced by interferon-alpha [in Japanese]. Nippon Kyobu Rinsho 1993; 52: 819–25

    Google Scholar 

  167. Watanabe N, Miura S, Yamaguchi E, et al. A case of interferon-alpha-induced pneumonitis [in Japanese]. Nippon Kyobu Shikkan Gakkai Zasshi 1993; 31: 1308–12

    PubMed  CAS  Google Scholar 

  168. Yamamoto S, Shimabara M, Yamamoto R, et al. A case of chronic hepatitis C with pneumonitis during interferon therapy [in Japanese]. Jpn J Gastroenterol 1993; 90: 2142–6

    CAS  Google Scholar 

  169. Motegi K, Yamada S, Samya S, et al. An autopsied case of interstitial and infectious pneumonia appeared during interferon treatment for C-type chronic active hepatitis [in Japanese]. Jpn J Gastroenterol 1994; 91: 116–20

    Google Scholar 

  170. Kamitsukasa H, Ohtake M, Kawashima H, et al. Two cases of interstitial pneumonia induced by interferon therapy for chronic aggressive hepatitis type C [in Japanese]. Acta Hepatol Jpn 1993; 34: 478–83

    Article  Google Scholar 

  171. Reynolds HY. Interstitial lung diseases. In: Wilson JD, Braunwald E, Isselbacher KJ, et al., editors. Harrison’s principles of internal medicine. 12th ed. New York: McGraw-Hill, 1991: 1082–7

    Google Scholar 

  172. Brody AR, Bonner JC, Badgett A. Recombinant interferon-gamma reduces PDGF-induced lung fibroblast growth but stimulates PDGF production by alveolar macrophages in vitro. Chest 1993; 103: 121S

    Article  PubMed  CAS  Google Scholar 

  173. Kovarik J, Mayer G, Pohanka E, et al. Adverse effect of low-dose prophylactic human recombinant leukocyte interferon-alpha treatment in renal transplant recipients. Transplantation 1988; 45: 402–5

    Article  PubMed  CAS  Google Scholar 

  174. Ornellas de Souza MH, Abdelhay E, Silva MLM, et al. Late marrow allograft rejection following alpha-interferon therapy for hepatitis in a patient with paroxysmal nocturnal hemoglobinuria. Bone Marrow Transplant 1992; 9: 495–7

    Google Scholar 

  175. Pavord S, Sivakumaran M, Durrant S, et al. The role of alpha interferon in the pathogenesis of GVHD. Bone Marrow Transplant 1992; 10: 477

    PubMed  CAS  Google Scholar 

  176. Klingemann HG, Grigg AP, Wilkie-Boyd K, et al. Treatment with recombinant interferon early after bone marrow transplantation inpatients at high risk for relapse. Blood 1991; 98: 3306–11

    Google Scholar 

  177. Weiden PL, Sullivan KM, Flounoy N, et al. Antileukemic effect of chronic graft-versus-host disease. N Engl J Med 1987; 304: 1529–33

    Article  Google Scholar 

  178. Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555–62

    PubMed  CAS  Google Scholar 

  179. Hess AD, Jones RJ, Morris LE, et al. Autologous graft-versus-host disease: a novel approach for antitumor immunotherapy. Human Immunol 1992; 34: 219–24

    Article  CAS  Google Scholar 

  180. Sawamura M, Murayama K, Ui G, et al. Plasma cell leukemia with alpha-interferon therapy in myeloma [correspondence]. Br J Haematol 1992; 82: 631

    Article  PubMed  CAS  Google Scholar 

  181. Blade J, Lopez-Guillermo A, Tassies D, et al. Development of aggressive plasma cell leukemia under interferon-alpha therapy. Br J Haematol 1991; 79: 523–4

    Article  PubMed  CAS  Google Scholar 

  182. Itoh Y, Okanoue T, Enjyo F, et al. Elevated interleukin-6 and gamma-globulin during interferon therapy of hepatitis B. Am J Gastroenterol 1992; 87: 1485–7

    PubMed  CAS  Google Scholar 

  183. Arico M, Maggiore G, De Stefano P, et al. Acute B-lineage lymphoid malignancy after interferon therapy for chronic viral hepatitis. Blood 1994; 83: 869–70

    PubMed  CAS  Google Scholar 

  184. Ohtsu T, Sakaki Y, Tanizaki H, et al. Development of pseudo-lymphoma of liver following interferon-alpha therapy for chronic hepatitis B. Intern Med 1994; 33: 18–22

    Article  PubMed  CAS  Google Scholar 

  185. Spielberger RT, Dickstein JI, Le Beau MM, et al. Acute myeloid leukemia following interferon-alpha treatment of hairy cell leukemia. Br J Haematol 1993; 83: 519–20

    Article  PubMed  CAS  Google Scholar 

  186. Warrell RP. Retinoid resistance. Lancet 1993; 341: 126

    Article  PubMed  Google Scholar 

  187. Bork K, Brauninger W, Rohnborn W. Metastases of malignant melanoma due to interferon-alpha 2a? [letter]. Dermatologica 1988; 177: 249–50

    Article  PubMed  CAS  Google Scholar 

  188. Mitoro A, Yoshikawa M, Yamamoto K, et al. Exacerbation of ulcerative colitis during alpha-interferon therapy for chronic hepatitis C. Intern Med 1993; 32: 327–31

    Article  PubMed  CAS  Google Scholar 

  189. Pecorani P. Colite ulcerosa in corso di leucemia a cellule capellute. Descrizione di un caso. Recenti Prog Med 1991; 82: 269–71

    Google Scholar 

  190. Yasumori K, Aramaki T, Mizuta Y, et al. Exacerbation of ulcerative colitis and chronic hepatitis by the treatment with interferon for chronic hepatitis B [in Japanese]. Jpn J Gastroenterol 1995; 92: 1066–70

    CAS  Google Scholar 

  191. Sparano JA, Dutcher JP, Kaleya R, et al. Colonic ischemia complicating immunotherapy with interleukin-2 and interferon-alpha. Cancer 1991; 68: 1538–44

    Article  PubMed  CAS  Google Scholar 

  192. Kanda Y, Shigeno K, Kinoshita N, et al. Sudden hearing loss associated with interferon. Lancet 1994; 343: 1134–5

    Article  PubMed  CAS  Google Scholar 

  193. Cole RR, Jahrsdoerfer RA. Sudden hearing loss: an update. Am J Otol 1988; 9: 211–5

    PubMed  CAS  Google Scholar 

  194. Panitch HS, Hirsch RL, Schindler J, et al. Treatment of multiple sclerosis with gamma interferon: exacerbations associated with activation of the immune system. Neurology 1987; 37: 1097–102

    Article  PubMed  CAS  Google Scholar 

  195. Vallbracht A, Treuner J, Flehmig B, et al. Interferon-neutralizing antibodies in a patient treated with human fibroblast interferon. Nature 1981; 289: 496–7

    Article  PubMed  CAS  Google Scholar 

  196. Antonelli G, Currenti M, Turriziani O, et al. Neutralizing antibodies to interferon alpha: relative frequency in patients treated with different interferon preparations. J Infect Dis 1991; 163: 882–5

    Article  PubMed  CAS  Google Scholar 

  197. Itri LA, Campion M, Dennin RA, et al. Incidence and clinical significance of neutralizing antibodies in patients receiving recombinant interferon alfa-2a by intramuscular injection. Cancer 1987; 59: 668–74

    Article  PubMed  CAS  Google Scholar 

  198. Antonelli G, Currenti M, Turriziani O, et al. Relative frequency of non-neutralizing antibodies to interferon (IFN) in patients treated with different IFN-alfa preparations. J Infect Dis 1992; 165: 593–4

    Article  PubMed  CAS  Google Scholar 

  199. Ikeda Y, Miyake K, Toda G, et al. Detection of anti-interferon-alpha 2a antibodies in chronic liver disease. J Gastroenterol Hepatol 1989; 4: 411–8

    Article  PubMed  CAS  Google Scholar 

  200. Lok ASF, Lai CL, Leung EKY. Interferon antibodies may negate the antiviral effects of recombinant alpha-interferon treatment in patients with chronic hepatitis B virus infection. Hepatology 1990; 12: 1266–70

    Article  PubMed  CAS  Google Scholar 

  201. von Wussow, Freund M, Block B, et al. Clinical significance of anti-IFN-alpha antibody titers during interferon therapy. Lancet 1987; ii: 635–6

    Article  Google Scholar 

  202. Dianzani F. Interferon treatments: how to use an endogenous system as a therapeutic agent. J Interferon Res 1992 May; spec issue: 109–18

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Third Department of Internal Medicine, Nara Medical University, 840 Shijo-cho, Kashihara, Nara, 634, Japan

    Masahide Yoshikawa, Hiroshi Fukui & Tadasu Tsujii

Authors
  1. Masahide Yoshikawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hiroshi Fukui
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tadasu Tsujii
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yoshikawa, M., Fukui, H. & Tsujii, T. Immunological Adverse Effects of Interferon Treatment. Clin Immunother 4, 361–375 (1995). https://doi.org/10.1007/BF03259299

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03259299

Keywords

Search

Navigation